Abraxane

Type: Product

Name: Abraxane

First reported May 23 2013 - Updated 20 hours ago - 1 reports

4 Healthcare Stock Stories Prescribed For Investors

Chembio Diagnostics ( NASDAQ:CEMI ): Closing price $4.50 Chembio announced Thursday that it has won a cooperative research agreement with a United States government agency for as much as $750,000 for an eight-month development project. The company ... [Published Wall St. Cheat Sheet - May 23 2013]

Entities: Howard Solomon, Celgene Corporation, Health Care, Stent

First reported May 24 2013 - Updated May 24 2013 - 2 reports

FDA Food & Drug Administration

Priority FDA Review for Celgene's Abraxane - Analyst Blog

Celgene Corporation (CELG) recently announced that the US Food and Drug Administration (FDA) will review the supplemental New Drug Application (sNDA) for cancer drug Abraxane on a priority basis.We note that Abraxane is already available in many countries ... [Published Quote.com Spain - May 24 2013]

Entities: Abraxane, Celgene Corporation, FDA Food & Drug Administration, Gemzar

First reported May 23 2013 - Updated May 24 2013 - 13 reports

Celgene sNDA of Abraxane obtains FDA priority review status

Celgene International has obtained FDA priority review status for Abraxane (paclitaxel protein-bound particles for injectable suspension) supplemental new drug application (sNDA).The application covers the use of Abraxane and gemcitabine combination therapy ... [Published Pharmaceutical Business Review - May 24 2013]

Entities: Abraxane, Celgene Corporation, Pancreatic Cancer, gemcitabine, Metastatic

First reported May 24 2013 - Updated May 24 2013 - 1 reports

Omeros Corp

Omeros Announces INDA for OMS824 Cleared by FDA; Celgene Announces FDA Grants Priority Review for ABRAXANE

Below is a look at some of the headlines for companies that made news in the healthcare sector on May 23, 2013.Omeros Corporation (NASDAQ: OMER) announced its Investigational New Drug Application (IND) to evaluate OMS824 in Huntington's disease has been ... [Published BioMedReports - May 24 2013]

Entities: Huntington's Disease, Omeros Corp, Abraxane, FDA Food & Drug Administration, Celgene Corporation

First reported May 23 2013 - Updated May 23 2013 - 1 reports

Celgene Corporation

Celgene (CELG) $123.02 down $0.42...

Today 11:09 AM ET (S&P Capital IQ)PrintSTRATEGY: Look at the July 120 covered call. For each 100 shares of Celgene (CELG) stock you buy, sell one July 120 covered call option for a $115.07 ($123.02 - $7.95) debit or better. That's potentially a 4.3% assigned ... [Published TD Ameritrade - May 23 2013]

Entities: Celgene Corporation, Abraxane, Standard & Poor's

First reported May 22 2013 - Updated May 22 2013 - 1 reports

Celgene's Management Presents at 2013 UBS Global Healthcare Conference (Transcript)

Celgene Corporation (CELG) 2013 UBS Global Healthcare Conference Call May 22, 2013 11:30 AM ETMatt Roden - UBSHi good morning everybody. We are going to move on to the next company presenting here at the UBS Global Healthcare conference. My name is Matt ... [Published Seeking Alpha - May 22 2013]

Entities: Celgene Corporation, Abraxane, Psoriatic Arthritis, Psoriasis, Patient

First reported May 20 2013 - Updated May 20 2013 - 1 reports

Apple Inc

Celgene, Visa, Apple: Rob Bartolo's Likes, Dislikes

Posted 04:57 PM ETT. Rowe Price's website describes its $33.8 billion Growth Stock Fund as aiming for stocks whose price will grow and whose dividend yields will rise too.Right now, manager Rob Bartolo sees much more potential for price gains.The fund's ... [Published Investors Business Daily - May 20 2013]

Entities: Celgene Corporation, Apple Inc, Visa Europe, Dividend, Dividend Yield

First reported May 20 2013 - Updated May 20 2013 - 1 reports

CELGENE - Prospects Bright beyond Revlimid in MM - New Products + Label Expansion - new market research report

With our conservative view on Revlimid - opportunity in EU (no approval in NDMM and Maintenance setting), reimbursement in China, and patent challenges; we expect net product sales' CAGR (2013-17) of 17% (vs. CELG's guidance: 19%) including risk adjusted ... [Published TransWorldNews - May 20 2013]

Entities: Celgene Corporation, European Union, Abraxane, Prescription Drug User Fee Act

First reported May 15 2013 - Updated May 15 2013 - 2 reports

i"Sorrento Therapeutics and Igdrasol acquire distribution rights for Cynviloq

5 minutes ago, 7:28am (ET) 05/15/2013 M2Sorrento Therapeutics, a development-stage biopharmaceutical company, and IGDRASOL, a developer of personalised nanoparticle paclitaxel, have acquired distribution rights for Cynviloq from Samyang Biopharmaceuticals ... [Published Zecco - May 15 2013]

Entities: Cynviloq, Igdrasol, Sorrento Therapeutics Inc

First reported May 13 2013 - Updated May 14 2013 - 2 reports

Sorrento, IGDRASOL announce European distribution rights to Samyang's Cynviloq

Sorrento Therapeutics (STI) and IGDRASOL have acquired exclusive distribution rights from Samyang Biopharmaceuticals for Cynviloq in the European Union (EU).IGDRASOL had earlier acquired exclusive US distribution rights to Cynviloq, which is a next-generation, ... [Published Pharmaceutical Business Review - May 14 2013]

Entities: Igdrasol, Cynviloq, non-small cell lung cancer, Samyang Biopharmaceuticals, Vuong Trieu

First reported May 01 2013 - Updated May 01 2013 - 4 reports

OncoGenex (OGXI) to Initiate OGX-427 Phase 2 in Combo with ABRAXANE

OncoGenex Pharmaceuticals, Inc. (Nasdaq: OGXI) announced plans for the initiation of the Rainier trial, an investigator-sponsored, randomized, placebo-controlled Phase 2 trial evaluating OGX-427 in combination with ABRAXANE (paclitaxel protein-bound particles ... [Published Street Insider - May 01 2013]

Entities: OGX-427, Abraxane, OncoGenex Pharmaceuticals

First reported Apr 25 2013 - Updated Apr 25 2013 - 3 reports

UPDATE 1-Celgene raises 2013 profit forecast, shares rise

April 25 (Reuters) - Biotechnology firm Celgene Corp reported a first-quarter profit that edged past analysts' estimates on strong demand for its cancer drugs, Revlimid and Abraxane, and it raised its full-year earnings forecast. ... [Published Globe and Mail - Apr 25 2013]

Entities: Abraxane, Celgene Corporation, Biotechnology

Quotes

...as outside financial and legal advisors, has determined that privately held investment firm Royalty Pharma's revised offer (“Royalty Pharma Offer ") announced on Monday May 20, 2013 to acquire all of Elan's shares for $12.50 per share through its shell subsidiary Echo Pharma Acquisition Limited, substantially undervalues the company."

Omeros Announces INDA for OMS824 Cleared by FDA; Celgene Announces FDA Grants Priority Review for ... [Published BioMedReports - May 24 2013]

More From BioPortfolio on "FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer"

FDA gives Priority Review to Celgene's ABRAXANE sNDA for advanced pancreatic cancer [Published BioPortfolio - May 23 2013]

More From BioPortfolio on "Celgene Announces U S FDA Grants Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer"

Celgene Announces U.S. FDA Grants Priority Review for ABRAXANE sNDA in Advanced Pancreatic Cancer [Published BioPortfolio - May 23 2013]

"Apple has been losing share in both smartphones and tablets, and earnings have been shrinking this year" Bartolo said

Celgene, Visa, Apple: Rob Bartolo's Likes, Dislikes [Published Investors Business Daily - May 20 2013]

More Content

sort by: Date \| Relevance
Oncogenex to Advance OGX-427 Development Zacks [Published Yahoo! Finance - 19 hours ago]
Priority FDA Review for Celgene's Abraxane - An... [Published Quote.com Spain - May 24 2013]
Priority FDA Review for Celgene's Abraxane Zacks [Published Yahoo! Finance - May 24 2013]
Celgene anuncia que FDA dos EUA concede revisão... [Published Business Wire Health News - May 24 2013]
Celgene sNDA of Abraxane obtains FDA priority r... [Published Pharmaceutical Business Review - May 24 2013]
Celgene宣布用于晚期胰腺癌治疗的ABRAXANE®补充新药申请获美国FDA优先审查资格 [Published Business Wire Health News - May 24 2013]
Celgene teilt mit, dass die US-amerikanische Ar... [Published Business Wire Health News - May 24 2013]
Celgene Announces U.S. FDA Grants Priority Revi... [Published Technology Networks - May 24 2013]
Celgene annonce que la FDA accorde un traitemen... [Published Business Wire Health News - May 24 2013]
Omeros Announces INDA for OMS824 Cleared by FDA... [Published BioMedReports - May 24 2013]
4 Healthcare Stock Stories Prescribed For Inves... [Published Wall St. Cheat Sheet - May 23 2013]
Investing in Cancer Research Is Worth the Risk:... [Published InvestorIdeas.com - May 23 2013]
Celgene International S??rl Announces U.S. FDA ... [Published BioSpace - May 23 2013]
Samenvatting: Celgene meldt dat FDA Priority Re... [Published Business Wire Health News - May 23 2013]
Celgene anuncia que la FDA de Estados Unidos ha... [Published Business Wire Health News - May 23 2013]
Celgene (CELG) $123.02 down $0.42... [Published TD Ameritrade - May 23 2013]
McDonald’s Initiates a Dividend, Seagate Gets A... [Published Wall St. Cheat Sheet - May 23 2013]
McDonald’s Initiates a Dividend, Seagate Gets A... [Published Wall St. Cheat Sheet - May 23 2013]
US EQUITIES OPENING HEADLINES INCLUDING: Micros... [Published Proactiveinvestors United Kingdom RSS feed - May 23 2013]
Celgene: FDA Grants Priority Review For ABRAXAN... [Published RTTNews.com - May 23 2013]
FDA gives Priority Review to Celgene's ABRAXANE... [Published BioPortfolio - May 23 2013]
Celgene: FDA Gives Priority Review to ... [Published ADVFN UK - May 23 2013]
Celgene Announces U.S. FDA Grants Priority Revi... [Published BioPortfolio - May 23 2013]
Celgene: FDA Gives Priority Review to Supplemen... [Published EuroInvestor - May 23 2013]
CELGENE CORPORATION: Celgene : FDA Gives Priori... [Published 4 Traders - May 23 2013]
Celgene Announces FDA Grants Priority Review fo... [Published Benzinga.com - May 23 2013]
CELGENE CORPORATION : Celgene Announces U.S. FD... [Published 4 Traders - May 23 2013]
Celgene Announces U.S. FDA Grants Priority Revi... [Published StockHouse USA - May 23 2013]
Celgene Announces U.S. FDA Grants Priority Revi... [Published BioPortfolio - May 23 2013]
Celgene Announces U.S. FDA Grants Priority Revi... [Published Business Wire Health News - May 23 2013]